ProQR Therapeutics (PRQR) Expected to Announce Earnings on Wednesday

ProQR Therapeutics (NASDAQ:PRQR) is expected to announce its earnings results before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $6.22 million for the quarter.

ProQR Therapeutics Trading Down 5.2 %

PRQR stock opened at $2.02 on Wednesday. The company’s 50-day moving average price is $2.38 and its 200 day moving average price is $2.64. The company has a market cap of $164.99 million, a P/E ratio of -6.31 and a beta of 0.25. ProQR Therapeutics has a 52 week low of $1.61 and a 52 week high of $4.62.

Analyst Ratings Changes

Several analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. JMP Securities reaffirmed a “market outperform” rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 28th. Chardan Capital reiterated a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Finally, Oppenheimer initiated coverage on ProQR Therapeutics in a research report on Friday, January 10th. They issued an “outperform” rating and a $15.00 target price on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $8.83.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).